ATNG Ouch..... .006

KIWI Getting pounded this afternoon....

I see NEOM is going to be the standard for awhile

ATNG Got a buy in .0061

Don't worry "I'll be back"

HYTT getting noticed again

CYGX someone lost some cash....

Trade executed at .6450

AMEP saw a 100K purchase at .072

It's Ok as you get older you have premature executions...

Profit is profit..

AMEP

NITE move bid up to .072... good sign... no one selling...

Dont you think you have pumped this enough?

http://www.investorshub.com/boards/profile.asp?User=2261

Anyone experienced this..

I have a trade in to sell at bid to clean up my trading account.

There are 2 MM's at the bid

Trade has not executed for an hour?

AMEP I agree they know news is coming soon...

They are up to old tricks...

AMEP look at that spread nobody wants to sell

BWLRF NEWS OUT

Breakwater Resources Ltd.


N MARKET GUIDE INC
G
K Copyright (c) 2003, Market Guide Inc., All rights reserved
G TABLE OF CONTENTS
L
Oca;BWR[MG]/2 L<<< Company Description
Oca;BWR[MG]/3 L<<< Quarterly Summary
Oca;BWR[MG]/4 L<<< Company To Industry Ratio Comparison
Oca;BWR[MG]/5 L<<< Share Ownership & Price Performance
Oca;BWR[MG]/6 L<<< Capitalization, Officers & Address
Oca;BWR[MG]/7 L<<< Annual Income Statements
Oca;BWR[MG]/8 L<<< Annual Income Statements - Continued
Oca;BWR[MG]/9 L<<< Quarterly & Year To Date Income Statements
Oca;BWR[MG]/10 L<<< Annual & Quarterly Balance Sheets
Oca;BWR[MG]/11 L<<< Annual & Year To Date Statement of Cash Flows
G
G
G
OComplete Financials: G March 2003 OExchange G OTC
O G OFY END G DEC
L ISSUE DATA (09/12/03) PER SHARE DATA RATIOS
OPrice $ G 0.24 OEPS (TTM) $ G -0.06 OP/E (TTM) G NM
O52W High $ G 0.24 ODiv. Rate $ G 0.00 OYield G NA %
O52W Low $ G 0.05 OBook Value $ G 0.33 OPrice/Book G 0.73
OShrs Out G 196.50 Mil OCash $ G 0.02 OROE (TTM) G -16.95 %
OFloat G 121.80 Mil ORev (TTM) $ G 0.65 OROA (TTM) G -7.00 %
OMon. Vol G 1.43 Mil O G OCurr. Ratio G 0.76
OBeta G 1.31 O G OLT Dbt/Eqty G 0.02
O BRIEF: G BWLRF is a natural resources company engaged in the
G acquisition, exploration, development and mining of base
G and precious metals deposits, primarily zinc, lead and
G silver, in North and Central America and Tunisia. For the
G 3 months ended 3/31/03, net revenues fell 8% to C$30.5M.
G Net income totaled C$69K, vs. a loss of C$3.3M. Results
G reflect a decrease in sales volumes, offset by C$5M gain on
G U.S. dollar denominated debt.
G

G L HISTORICAL QUARTERLY RESULTS ($000)
LREVENUE 2000 2001 2002 2003
O1st Qtr MAR G 36,125 44,917 33,228 30,478
O2nd Qtr JUN G 45,562 32,951 38,723
O3rd Qtr SEP G 55,068 44,732 38,587
O4th Qtr DEC G 29,833 39,201 58,078
LEPS (Canadian Dollars per share)
O1st Qtr MAR G 0.060 -0.040 -0.030 0.000
O2nd Qtr JUN G 0.040 -0.010 0.010
O3rd Qtr SEP G 0.080 -0.770 -0.090
O4th Qtr DEC G -0.270 -0.110 -0.010
G
G FY'94-'95 are restated for a change in accounting policy.
G FY'99 & FY'00 fncls. are restated. FY'00-'01 fncls. are
G reclassified.
G
L DIVIDENDS EMPLOYEES
O Last Dividend Decl. G $ NA O # Employees G 891
O Last Div Ex-Date G NA O Sales/Employee (TTM) G 136,504
O Last Div Pay Date G NA O Net. Income/Empl.(TTM G) NM
LCOMPANY COMPARISON TO THE MINING & MINERAL RESOURCES AND S&P 500 AGGREGATES
LVALUATION RATIOS: COMPANY INDUSTRY S&P 500
OP/E Ratio G NM 30.91 25.82
ODividend Yield G NA 2.10 2.16
OPrice to Tangible Book G 0.73 3.72 7.87
OPrice to Book G 0.73 3.08 4.62
OPrice to Free Cash Flow G 30.00 43.38 32.18
LGROWTH STATISTICS:
O3 Yr Rev Growth G 8.86 11.86 8.43
O3 Yr EPS Growth G NM 3.06 10.35
O3 Yr Div Growth G NM 6.87 8.57
OReinvestment Rate G 100.00 77.98 69.77
LPROFITABILITY RATIOS:
ONet Profit Margin G -9.98 12.01 11.49
OReturn on Equity G -16.95 11.55 17.38
OInterest Coverage G -2.63 8.08 12.01
LFINANCIAL STRENGTH RATIOS:
OCurrent Ratio G 0.76 2.22 1.69
OLT Debt to Equity G 0.02 0.44 0.81
OTotal Debt to Equity G 0.81 0.56 1.11
L INSTITUTIONAL OWNERSHIP INSIDER TRADING (Prev. 6 months)
G O % Shares Out. Owned G 0.46 % ONet Insider Trades G 0
O # of Institutions G 9 O# Buy Transactions G 0
O Total Shs Held G 0.896 Mil O# Sell Transactions G 0
O 3 Mo. Net Purch. G -2.057 Mil ONet Shares Bought G 0.000 Mil
O 3 Mo. Shs Purch. G 0.477 Mil O# Shares Bought G 0.000 Mil
O 3 Mo. Shs Sold G 2.535 Mil O# Shares Sold G 0.000 Mil
G
O 4 Week Price % Change G 20.0% O 4 Week Rel. Price % Change G 16.7%
O 13 Week Price % Change G 71.4% O 13 Week Rel. Price % Change G 66.4%
O 26 Week Price % Change G 71.4% O 26 Week Rel. Price % Change G 40.2%
O 52 Week Price % Change G 166.7% O 52 Week Rel. Price % Change G 132.9%
OYTD Week Price % Change G 140.0% OYTD Week Rel. Price % Change G 107.3%
G
G
LMARKET MAKERS: G HRZG TSCO
G
G
G
G
OEQUITY: GCommon Stock no Par, 3/03, unlim. auth., 196,497,000 issd.
GInsiders own approx. 1%. Dundee Bancorp, Inc. owns approx.
G37%. IPO: NA. 6/87, 4.2M shares issd. in acquisition of
GNovamin. 6/95, 1-for-400 reverse stock split. 5/00
Gacquired Bouchard-Hebert and Langlois mines. *FY'00 Q's are
Grestated. FY'01 Q's are being restated.
G
OOFFICERS: G Garth McRae, Chmn., Colin K. Benner,
GPres./COO/CEO, Rene R. Galipeau, Sr. VP-Fin./CFO, Norman K.
GCalder, Treas. TRANSFER AGENT: Computershare Trust
GCompany of Canada. Company incorporated 1979 in British
GColumbia. Direct inquiries to: E. Ann Wilkinson, Secy.
O ADDRESS & PHONE NUMBERS ADR INFORMATION
GBreakwater Resources Ltd. Shares Per ADR 1.00
G95 Wellington Street West Currency Name Canadian Dollars
GSuite 2000 EXCH RATE (Local Curr./US $):
GToronto, ON M5J 2 Most Recent 1.364
G Year Average 1.364
GPHONE: (416) 363-4798 Year End 1.371
G FAX: (416) 363-1315
LANNUAL INCOME STATEMENT ($000)
L 12M 12/31/99 12M 12/31/00 12M 12/31/01 12M 12/31/02
L RSTD12/31/01
ONet Sales G 0 0 0 0
OGross Revenue G 236,135 301,850 304,037 305,354
OTreatment/Mark. Cost G -105,440 -135,262 -142,236 -136,738
O Total Revenue G 130,695 166,588 161,801 168,616
OOperating Costs G 90,453 105,561 153,187 147,653
OCost of Revenue G 17,361 24,247 32,106 30,459
OUnusual Inc./Expense G 0 27,142 70,281 0
OGeneral & Admin. G 5,580 7,322 7,481 6,198
OInterest G 4,001 8,192 7,946 5,122
OOther Operating G -497 -230 -2,886 -36
OForeign Exchange G -896 1,399 4,720 -669
O Total Expenses G 116,002 173,633 272,835 188,727
O Operating Income G 14,693 -7,045 -111,034 -20,111




LANNUAL INCOME STATEMENT ($000) (Contd.)
L 12M 12/31/99 12M 12/31/00 12M 12/31/01 12M 12/31/02
L RSTD12/31/01
O Operating Income G 14,693 -7,045 -111,034 -20,111
OAfflt. Loss Equity G 0 0 0 0
O Income Before Taxes G 14,693 -7,045 -111,034 -20,111
OIncome Taxes G 1,776 1,704 24 -224
O Income After Taxes G 12,917 -8,749 -111,058 -19,887
OUS GAAP Adjustment G 0 0 0 0
O Pri/Bas EPS Ex. XOrd G 0.166 -0.080 -0.924 -0.117
OExtraordinary Item G 0 0 0 0
O Pri/Bas EPS In. XOrd G 0.166 -0.080 -0.924 -0.117
OPrimary/Basic Avg Sh G 77,691.00 109,033.00 120,166.00 169,675.00
OCommon Dividends/Shr G 0.0000 0.0000 0.0000 0.0000






LSELECTED INCOME STATEMENT ITEMS ($000)
L QUARTERS YEAR TO DATE
L 3M 03/31/02 3M 03/31/03 3M 03/31/02 3M 03/31/03
ORevenue G 33,228 30,478 33,228 30,478
OOperating Expenses G 36,154 30,367 36,154 30,367
O Operating Income G -2,926 111 -2,926 111
ONon-Operating Income G 0 0 0 0
ONon-Operating Expenses G 0 0 0 0
O Income Before Taxes G -2,926 111 -2,926 111
OIncome Taxes G 345 42 345 42
OAdjustments to Income G 0 0 0 0
O Inc. for Primary EPS G -3,271 69 -3,271 69
O Pri/Bas EPS Ex. XOrd G -0.035 0.000 -0.035 0.000
ODisc Opns + Xord Items G 0 0 0 0
O Pri/Bas EPS In. XOrd G -0.035 0.000 -0.035 0.000
OPrimary/Basic Avg Sh G 94,455.00 195,509.00 94,455.00 195,509.00
O Dilutd EPS Excl XOrd G -0.035 0.000 -0.035 0.000
O Dilutd EPS Incl XOrd G -0.035 0.000 -0.035 0.000
OCommon Dividends/Shr G 0.000 0.000 0.000 0.000

LSELECTED BALANCE SHEET ITEMS ($000)
L YEAR ENDING QUARTER ENDING
L 12/31/01 12/31/02 03/31/02 03/31/03
OCash & ST Investments G 3,373 6,435 3,118 5,845
OReceivables G 10,224 23,982 9,991 10,904
O Total Current Assets G 95,957 87,111 102,775 72,906
OLT Investments G 0 0 0 0
OFixed Assets G 152,372 134,882 148,100 126,925
O Total Assets G 251,569 223,380 254,115 201,293
OAccounts Payable G 43,985 25,577 37,862 22,039
OST Debt & Curr LTD G 34,030 30,227 91,224 70,106
O Total Current Liab. G 90,909 64,827 141,188 96,615
OLT Debt & Cap Leases G 46,376 48,438 3,187 1,396
O Total Liabilities G 152,993 127,784 158,640 112,732
OPreferred Stock G 0 0 0 0
OCommon/Paid In Capital G 240,699 259,341 240,832 260,063
ORetained Earnings G -158,968 -178,855 -162,239 -178,786
O Total Equity G 98,576 95,596 95,475 88,561
OShares Outstanding G 93,848 193,281 188,910 196,497

LSELECTED STMT OF CASH FLOWS - INDIRECT METHOD ($000)
L ANNUAL YEAR TO DATE
L 12M 12/31/01 12M 12/31/02 3M 03/31/02 3M 03/31/03
ONet Income G -111,058 -19,887 -3,271 69
ODepreciation & Amort. G 27,980 27,565 6,618 6,030
ONon Cash Items G 73,717 969 778 -5,666
O Total Operating CF G 33,099 -2,551 -12,068 4,575
OCapital Expenditures G -21,662 -10,971 -2,297 -3,264
O Total Investing CF G -20,700 -11,121 -2,297 -3,339
ODividends Paid G 0 0 0 0
OSale (Purch.) of Stock G 902 17,907 133 54
ONet Borrowings G -14,696 -1,105 13,977 -1,880
O Total Financing CF G -13,794 16,802 14,110 -1,826
OExchange Rate Effect G 0 0 0 0
ONet Change In Cash G -1,395 3,130 -255 -590
OOper CF-Cap Exp-Div Pd G 11,437 -13,522 -14,365 1,311



KCopyright (c) 2003, Market Guide Inc., All rights reserved
G

Sep-13-2003 13:35 GMT
Symbols:
CA;BWR US;BWLR
Source B Market Guide

CYGX NEWS OUT

CytoGenix Adds Business and Scientific Leaders to Its Board of Directors



Business Editors/Health/Medical Writers

HOUSTON--(BUSINESS WIRE)--Sept. 15, 2003--CytoGenix Inc.
(OTCBB:CYGX) announced Monday that Dr. Cy Stein and Mr. Raymond L.
Ocampo Jr. have joined the CytoGenix board of directors.
Dr. Stein is a pioneer in the field of gene medicine. He has
authored approximately 150 scientific articles, reviews and
commentaries. He holds several patents for inventions in this field
and serves on the scientific advisory boards of Genta Inc., Salus
Inc., Arc Pharmaceuticals Inc. and Cureon A/S, a Danish biotech
company. Dr. Stein received a Ph.D. in chemistry from Stanford
University and the M.D. from the Albert Einstein College of Medicine.
He trained as a medical oncologist at the New York Hospital/Cornell
Medical Center and the National Cancer Institute. For thirteen years,
he taught and conducted research at Columbia University College of
Physicians and Surgeons. Recently he received an appointment to the
post of professor of medicine, urology and molecular pharmacology at
the Albert Einstein College of Medicine. Dr. Stein is co-editor of the
journal Antisense and Nucleic Acid Drug Development and serves on the
editorial advisory boards of several other publications, including
Bioconjugate Chemistry and Clinical Cancer Research.
Mr. Ocampo served as senior vice president, general counsel &
secretary at Oracle Corp., the world's second-largest software
company, until 1996 when he retired. During his decade-long tenure,
Oracle's annual revenues grew from $50 million to more than $5
billion. Before joining Oracle, Mr. Ocampo specialized in antitrust
and complex litigation with various law firms in San Francisco and
taught professional responsibility, trial practice and legal writing
and research at Hastings College of the Law. After retiring from
Oracle, Mr. Ocampo co-founded and served as executive director of the
Berkeley Center for Law & Technology, the leading intellectual
property program in the U.S. He received his undergraduate degree from
U.C.L.A. and his law degree from Boalt Hall School of Law at U.C.
Berkeley. He currently serves on the boards of numerous corporate and
nonprofit organizations.
"We are very fortunate to attract individuals of this caliber to
guide us in directing our enterprise as we accelerate our commercial
and financial growth. Both have the proven experience, knowledge and
talents that will be invaluable in the next stage of our company's
development," states Dr. Malcolm Skolnick, chairman/CEO. "These
individuals will also bring the company into compliance with the
spirit of corporate governance practices and statutes," adds Dr.
Skolnick.
CytoGenix Inc. is a biopharmaceutical company that develops and
markets innovative products and services based on its proprietary DNA
expression technology. CytoGenix has products in pre-clinical
development, including anti-herpes, anti-psoriasis and
anti-inflammatory topical creams. The company owns a U.S. patent for
its core DNA expression technology and has 40 international or U.S.
pending patent applications.
SAFE HARBOR: Except for statements of historical fact, the
statements in this press release are forward-looking. Such statements
are subject to a number of risks and uncertainties that could cause
actual results to differ materially from the statements made. These
factors include, but are not limited to, general economic conditions,
risks associated with the acceptance of new products, competition and
other factors more fully detailed in the company's filings with the
Securities and Exchange Commission. Additional information about
CytoGenix and its technology can be found on the Web site at
www.cytogenix.com.

--30--JV/ho*

CONTACT: CytoGenix Inc., Houston
Juan Ferreira, 407-774-9949

KEYWORD: TEXAS
INDUSTRY KEYWORD: PHARMACEUTICAL BIOTECHNOLOGY MANAGEMENT CHANGES
SOURCE: CytoGenix Inc.

CYGX moving up

BWLRF Upticking...em

CYGX upticking.....

HLTH

Make a prediction... stock will gain 30 - 40% by year end

MURPHY'S LAWS ON WORK

A pat on the back is only a few centimeters from a kick in the pants.

Don't be irreplaceable, if you can't be replaced, you can't be promoted.

The more crap you put up with, the more crap you are going to get.

You can go anywhere you want if you look serious and carry a clipboard.

Eat one live toad the first thing in the morning and nothing worse will happen to you the rest of the day.

Never ask two questions in a business letter. The reply will discuss the one you are least interested in, and say nothing about the other.

When the bosses talk about improving productivity, they are never talking about themselves.

If at first you don't succeed, try again. Then quit. No use being a damn fool about it.

There will always be beer cans rolling on the floor of your car when the boss asks for a ride home from the office.

Mother said there would be days like this, but she never said there would be so many.

Keep your boss's boss off your boss's back. This is what I'm doing wrong.

Everything can be filed under "miscellaneous."

Never delay the ending of a meeting or the beginning of a cocktail hour.

To err is human, to forgive is not company policy.

Anyone can do any amount of work provided it isn't the work he is supposed to be doing.

Important letters that contain no errors will develop errors in the mail.

The last person that quit or was fired will be the one held responsible for everything that goes wrong - until the next person quits or is fired.

There is never enough time to do it right the first time, but there is always enough time to do it over.

The more pretentious a corporate name, the smaller the organization. (For instance, The Murphy Center for Codification of Human and Organizational Law, contrasted to IBM, GM, AT&T ...).

If you are good, you will be assigned all the work. If you are really good, you will get out of it.

You are always doing something marginal when the boss drops by your desk.

People are always available for work in the past tense.

If it wasn't for the last minute, nothing would get done.

At work, the authority of a person is inversely proportional to the number of pens that person is carrying.

When you don't know what to do, walk fast and look worried.

You will always get the greatest recognition for the job you least like.

No one gets sick on Wednesdays.

When confronted by a difficult problem you can solve it more easily by reducing it to the question, "How would the Lone Ranger handle this?"

The longer the title, the less important the job.

Machines that have broken down will work perfectly when the repairman arrives.

An "acceptable" level of employment means that the government economist to whom it is acceptable still has a job.

Once a job is fouled up, anything done to improve it makes it worse.

All vacations and holidays create problems, except for one's own.

Success is just a matter of luck, just ask any failure.

This message is SPAM

Thanks Matt Finally I got it figured out...

Appreciate it...

take care

Good job hope this works

Thanks

No wonder I can't get it inserted... thanks

anyone know how to post a jpeg into a signature message or an animated gif?

could not find info at IHUB knowledge center.

anyone know how I can insert a jpeg from my computer into a message?

Corruption as bad as the stock market...

Likewise....

Got it already picked out



can you help with the down payment please.....

Thats right, I just need to make enough cash to buy a boat, move near a lake, and buy a 12 pack... so ya looking for a new neighbor... LOL

I agree...

Round by round I had D' winning by 2 rounds...

Men, on the other hand, plop down in front of the screen and that's it. The women ceases to exist. It is nice.

Oh my GOD ... a RB flashback...

Someone get my medicine...

Will it gap and run after that...

I'm in...

I was in DLGI for awhile "Hated it" hope you have better luck than I did...

Got a feeling you will be well rewarded next week on an AMEP purchase today....

Good luck..

Brig cant pm

Getting better but need a few good trades. I took a shot on IVOC NEVER CHASE A TRADE. Got caught up in hype... Thats why I'm staying away from NEOM until it settles down.

BWLRF

Still holding Omni?